Cell & Gene Therapy Capital Flows
While national venture capital funding for life sciences cooled by 18% year-over-year, Philadelphia's cell and gene therapy (CGT) sector bucked the trend, securing over $1.2B in Series B and C rounds in Q1 2024 alone.
Worked Data & Figures
| Company | Funding Round | Capital Raised |
|---|---|---|
| Spark Therapeutics (Expansion) | Corporate | $575M |
| Century Therapeutics | Post-IPO Follow-on | $150M |
Common Mistakes in Analysis
- Relying on outdated 2019 baselines without adjusting for remote work trends.
- Ignoring hyper-local neighborhood variations.
Frequently Asked Questions
What is the source of this data?
Primary data sourced from municipal tax records, Kastle Systems, and proprietary surveys.
How often is this updated?
We update these index figures quarterly.